NCT06485700 Peers and Technology for Adherence, Access, Accountability, and Analytics (PT4A)
| NCT ID | NCT06485700 |
| Status | Recruiting |
| Phase | — |
| Sponsor | NYU Langone Health |
| Condition | Cardiovascular Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,140 participants |
| Start Date | 2025-11-18 |
| Primary Completion | 2028-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,140 participants in total. It began in 2025-11-18 with a primary completion date of 2028-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Peer-based medication delivery decreases the cost of transportation and the opportunity cost of travel while HIT can support peer activities by facilitating targeted adherence counseling, teleconsultation, synchronization of clinical care, and pharmacy activities. The investigators have implemented a pilot program of door-to-door peer-based medication delivery and HIT in western Kenya, and preliminary data indicate improved adherence and blood pressure. However, the effectiveness of this implementation strategy is not fully established. Therefore, the objective of the study is to use the PRECEDE-PROCEED framework to conduct transdisciplinary implementation research to test the hypothesis that integrating peer delivery of medications with HIT (PT4A) improves medication adherence and reduces blood pressure among patients with uncontrolled hypertension in western Kenya.
Eligibility Criteria
Inclusion Criteria: • Adult participants enrolled in AMPATH's CDM Program with uncontrolled hypertension (SBP ≥ 140 or diastolic BP (DBP) ≥ 90) Exclusion Criteria: * hypertensive emergency requiring immediate medical attention, * terminal illness, and * inability to provide informed consent.
Contact & Investigator
Rajesh Vedanthan
PRINCIPAL INVESTIGATOR
NYU Langone Health
Frequently Asked Questions
Who can join the NCT06485700 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cardiovascular Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06485700 currently recruiting?
Yes, NCT06485700 is actively recruiting participants. Contact the research team at Rajesh.vedanthan@nyulangone.org for enrollment information.
Where is the NCT06485700 trial being conducted?
This trial is being conducted at Webuye, Kenya, Kitale, Kenya, Eldoret, Kenya.
Who is sponsoring the NCT06485700 clinical trial?
NCT06485700 is sponsored by NYU Langone Health. The principal investigator is Rajesh Vedanthan at NYU Langone Health. The trial plans to enroll 1,140 participants.